Morepen Laboratories (MOREPENLAB) Fundamentals 2026 — P/E 30.8x, Revenue Analysis | SniperIQ
Morepen Laboratories (MOREPENLAB) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹2,920 Crore, trading at ₹53.29 on the NSE. This SniperIQ fundamentals page covers Morepen Laboratories's valuation (P/E 30.8x, P/B 2.4x), profitability (net margin 5.3%), revenue (₹1,806 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Morepen Laboratories's market cap?
Morepen Laboratories (MOREPENLAB) has a market capitalization of approximately ₹2,920 Crore, trading at ₹53.29 on the NSE. Market cap moves with the live share price.
What is Morepen Laboratories's P/E ratio?
Morepen Laboratories's trailing twelve-month P/E ratio is 30.8x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Morepen Laboratories?
Morepen Laboratories runs a net profit margin of 5.3%, a gross margin of 37.8%, and an operating margin of 4.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Morepen Laboratories generate?
Morepen Laboratories reported revenue of ₹1,806 Crore for fiscal year 2026, with net income of ₹95 Crore and earnings per share (EPS) of 1.73. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Morepen Laboratories pay a dividend?
Morepen Laboratories offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Morepen Laboratories financially healthy?
Morepen Laboratories carries a debt-to-equity ratio of 0.17x and a current ratio of 2.37x, with a market beta of 0.70. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Morepen Laboratories a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Morepen Laboratories (MOREPENLAB) the key facts are: market cap ₹2,920 Crore, P/E 30.8x, revenue ₹1,806 Crore, 52-week range 33.05-64.58. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Morepen Laboratories's full fundamentals live
Get Morepen Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.